Neurocrine biosciences reports second quarter 2023 financial results and raises 2023 ingrezza sales guidance

Ingrezza® (valbenazine) second quarter net product sales of $440 million representing 26% year-over-year growth ingrezza® (valbenazine) 2023 net product sales guidance raised to $1.77 - $1.82 billion san diego, aug. 1, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the second quarter ended june 30, 2023 and raised net sales guidance for ingrezza in 2023. "ingrezza's performance reflects the significant benefit the medicine is providing to patients with tardive dyskinesia enabling us to raise guidance once again," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking